Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CADL
CANDEL THERAPEUTICS, INC.
NASDAQ
$13.07
▼ DOWN 4.95% (-0.68)

KEY STATISTICS

Market Cap$957.64 M
52w High$14.00
52w Low$4.35
Dividend Yield—
Frequency—
P/E-9.27
Volume1.24M
Shares Out.73.27M

COMPANY

LEADERSHIP

Paul-Peter Tak
CHIEF EXECUTIVE
Paul-Peter Tak

COMPENSATION 2026

Salary$743,592
Stock Awards$0
Incentive Plan Pay$396,653
All Other Comp.$288,289
Total$5,344,561

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 27, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
55

PRICE TARGET

Target High$23.00
Target Low$22.00
Target Median$22.50
Target Consensus$22.50

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$13.07 ▼ DOWN 4.95% (−$0.68)
$13.00$13.25$13.50$13.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.07

About Candel Therapeutics, Inc.

https://www.candeltx.com ↗

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies like CAN-2409 and CAN-3110 for various cancers, with multiple ongoing Phase I-III trials.

INDUSTRY

Biotechnology

A PRODUCT CANDEL THERAPEUTICS, INC. IS KNOWN FOR

CAN-2409 (aglatimagene besadenovec)
CAN-2409 (aglatimagene besadenovec)

CAN-2409, Candel Therapeutics' lead viral immunotherapy, delivers HSV-tk gene to tumor cells to induce death and stimulate immune response, currently in Phase 3 for prostate cancer and evaluated for other solid tumors.

COMPETITORS

COMPETITOR
CGON COMPARE
GNLX COMPARE
ONCY COMPARE
REPL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
77
LISTED HERE
13
RANKED BY POSITION SIZE
XBI
0.25% · 2.2M
VTI
0.00% · 2.0M
IWM
0.03% · 1.6M
SBIO
0.49% · 90.7K
CANC
0.53% · 86.3K
LABU
0.17% · 78.4K
XRSG.L
0.03% · 58.0K
BBC
0.96% · 36.6K
RSSL
0.03% · 30.1K
IBBQ
0.06% · 4.6K
BIB
0.03% · 2.6K
SZNE
0.05% · 940
RESM
0.03% · 114

INSTITUTIONAL OWNERSHIP

SHARES OWNED
52.10%
HOLDERS
129
TOP 12 OF 129 · RANKED BY POSITION SIZE
Fmr LLC
11.0M sh · $53.84M
Rtw Investments, LP
6.4M sh · $31.47M
Acorn Capital Advisors, LLC
3.5M sh · $17.21M
Blackrock, Inc.
3.1M sh · $15.23M
Saturn V Capital Management LLC
2.9M sh · $14.19M
Portolan Capital Management, LLC
2.9M sh · $14.18M
Vanguard Group Inc
2.3M sh · $13.02M
Northpond Ventures, LLC
1.9M sh · $13.41M
Vestal Point Capital, LP
1.1M sh · $5.51M
Millennium Management LLC
1.1M sh · $5.19M
Geode Capital Management, LLC
1.0M sh · $5.07M
Halter Ferguson Financial Inc.
904.1K sh · $4.43M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF TECHNOLOGY OFFICER
Tyagarajan Seshu
Sale · 7.0K shares
2026-08-17
★
OFFICER: CHIEF COMMERCIAL OFFICER
Sims Mark E.
Purchase · 285.0K shares
2026-07-06
★
Sims Mark E.
— · —
2026-07-06
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Barone Francesca
Sale · 23.4K shares
2026-06-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
NEUTRAL 1
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
B of A Securities NEUTRAL HC Wainwright & Co. BUY Citigroup BUY Canaccord Genuity BUY Stephens & Co. OVERWEIGHT Freedom Broker BUY

SECTORS PEERS

PEERPRICE
CTNM$17.05COMPARE
CAPR$9.59COMPARE
KYTX$8.37COMPARE
CABA$3.12COMPARE
EDIT$3.16COMPARE
PRQR$2.29COMPARE
GNLX$2.66COMPARE
ALDX$1.49COMPARE